Truist Securities Reiterates Buy on Tenet Healthcare, Raises Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has reiterated a Buy rating on Tenet Healthcare (NYSE:THC) and increased the price target from $120 to $130.

May 01, 2024 | 12:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities has reaffirmed its Buy rating on Tenet Healthcare and raised its price target from $120 to $130.
The reiteration of a Buy rating combined with an increased price target typically signals a strong bullish outlook from the analyst. This endorsement from a reputable analyst like David Macdonald could lead to increased investor confidence in Tenet Healthcare, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100